fielding acquisition agreement
Polish translation: umowa nabycia firmy Fielding Pharmaceutical Company
| GLOSSARY ENTRY (DERIVED FROM QUESTION BELOW) | ||||||
|---|---|---|---|---|---|---|
|
| 10:00 Jul 11, 2018 |
| English to Polish translations [PRO] Bus/Financial - Medical: Pharmaceuticals / farmakologia | |||||||
|---|---|---|---|---|---|---|---|
|
| ||||||
|  Selected response from: Frank Szmulowicz, Ph. D. United States Local time: 18:09 | ||||||
Grading comment
| |||||||
| Summary of answers provided | ||||
|---|---|---|---|---|
| 3 +1 | umowa nabycia firmy Fielding Pharmaceutical Company |
|
| Discussion entries: 5 | |
|---|---|
Answers
18 mins confidence: 
peer agreement (net): +1
peer agreement (net): +1umowa nabycia firmy Fielding Pharmaceutical Company Explanation: In December 2000, Novavax acquired privately owned Fielding Pharmaceutical Company (“Fielding”), based in St. Louis, Missouri, which sells, markets and distributes a proprietary line of pharmaceutical products focused on women’s health. The puchase method of accounting was used to account for the transaction. -------------------------------------------------- Note added at 19 mins (2018-07-11 10:20:03 GMT) -------------------------------------------------- Selling, general and administrative expenses were $4.7 million for 2001, compared to $1.3 million incurred for the same period in 2000, an increase of $3.4 million. This increase was due to a number of factors, including the sales and marketing costs to support product sales, the increases in personnel from the Fielding acquisition, the full effect of increases in administrative and executive employees in 2000 and 2001 to support our growth and the initiation of commercialization activities for ESTRASORB. In addition, we also expensed approximately $700,000 for goodwill amortization related to the Fielding acquisition and the acquisition of the AVC™ Product Line from King in January 2001 for $3.3 million. Research and development expenses were $3.8 million in 2001 compared to $2.1 million in 2000. This $1.7 million increase in research and development expenses is primarily due to NDA preparation and filing costs related to ESTRASORB and additional expenses to support the growth in research and development contracts. Product and another pharmaceutical product. NOVAVAX Product shall specifically exclude any pharmaceutical or related products owned by NOVAVAX as a direct result of the consummation of the Fielding Acquisition Agreement (as defined in the Note Purchase Agreement) so long as any such pharmaceutical product or related product does not include or use ESTRASORB™ or ANDROSORB™ technology or Know How. https://ir.novavax.com/static-files/ad3a136c-e89f-4725-b701-... |
| |
Grading comment
| ||
| Login to enter a peer comment (or grade) | ||
Login or register (free and only takes a few minutes) to participate in this question.
You will also have access to many other tools and opportunities designed for those who have language-related jobs (or are passionate about them). Participation is free and the site has a strict confidentiality policy.
KudoZ™ translation help
The KudoZ network provides a framework for translators and others to assist each other with translations or explanations of terms and short phrases.
See also:
Search millions of term translations